JAN 20, 2019 06:31 PM PST

Combination Therapeutic Effective for Leishmaniasis and HIV Patients

WRITTEN BY: Nouran Amin

In a study published in PLOS Neglected Diseases, a special combination therapy has been proven for efficacy in cases of coinfection with Visceral leishmaniasis (VL) and human immunodeficiency virus (HIV). As of now, the World Health Organization (WHO) recommends AmBisome monotherapy for treatment, however, the study proposed a combination therapy of AmBisome and another drug called ‘miltefosine’ to be more effective.

Learn more about Visceral Leishmaniasis (VL) and HIV Coinfection from a patient perspective:

Research has confirmed that 30 mg/kg of AmBisome is effective in 43-70% of patients with an HIV co-infection. However, AmBisome brings the proneness of toxicity and an increased risk of death. HIV increases the incidence of VL by altering it symptoms and worsening the illness along with treatment outcomes and rates of relapse.

Séverine Blesson and team, who are working on the Drugs for Neglected Diseases Initiative in Switzerland, began a compassionate use of clinical studies in a treatment facility in Northwest Ethiopia consisting of combining AmBisome and miltefosine. Measurements of efficacy were taken according to parasite clearance at 29 days and 58 days. Results showed that after 29 days measurements for efficacy was 50% for AmBisome and 67% for the combination therapy. At 58 days, 55% efficacy was measured for the monotherapy and 88% for the combination treatment.

HIV infection remains a challenge for the control of visceral leishmaniasis (VL) control.

Credit: PLOS Collections Blog - Biology & Life Sciences

The study showed no safety concerns about the combination therapy. "The results of this randomized trial strongly support a change in the treatment recommendations for HIV-VL co-infected patients," noted the researchers—however, they do caution, "these results, even if encouraging, cannot be extrapolated to other settings without reservation."

Source: Science Daily

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 22, 2019
Cardiology
NOV 22, 2019
Somethings Fishy With Omega 3 Claims
Each month nearly 20 million Americans turn to fish oil for heart disease prevention. Though it may sound healthy, this trend is troubling in the face of z...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
Does Modafinil Really Increase Brain Function?
Modafinil, often sold under the name “Provigil”, is a wakefulness-promoting drug used to treat excessive sleeping in conditions such as narcole...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
How does a drug for colorectal cancer work?
Colorectal cancer is a fatal and common disease, and treatment decisions are often based on what genes have been mutated in the development of the cancer. ...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
Investigating a common therapeutic in ADHD treatment
Attention-Deficit Hyperactivity Disorder (ADHD) is a widespread condition with variable underlying causes. A common therapeutic, called methylphenidate, se...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
Possible New Drug Targets for Glioblastoma
Scientists at Karolinska Institutet in Sweden were able to pinpoint 10 tumor-specific potential drug targets for the fatal and incurable brain cancer, glio...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
FDA Approves New Drug for Sickle Cell Disease
Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting...
Loading Comments...